{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Gebo KA"],"pubmed_abstract":["Background
Post-COVID conditions (PCC) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about early treatment, inflammation, and PCC.Methods
Among 883 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of CCP vs. control plasma with available biospecimens and symptom data, the association between early COVID treatment, cytokine levels and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14 and day 90 using a multiplexed sandwich immuosassay (Mesoscale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between COVID treatment, cytokine levels and PCC were examined using multi"],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2023.02.13.23285855"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9949202"],"repository":["biostudies-literature"],"pubmed_title":["Early Treatment, Inflammation and Post-COVID Conditions."],"pmcid":["PMC9949202"],"pubmed_authors":["Gebo KA","Huaman MA","Ruff J","Patel B","Habtehyimer F","McBee NA","Hanley D","Das P","Blair JE","Lane K","Baksh S","Sutcliffe CG","Hammitt LL","Shade D","Mosnaim GS","Paxton JH","Cachay ER","Currier JS","Ram M","Casadevall A","Klein SL","Kassaye S","Pekosz A","Gniadek T","Levine A","Heath SL","Bloch EM","Patel EU","Tobian AAR","Laeyendecker O","Sullivan DJ","Baker OR","Gawad AL","Meisenberg B","Anjan S","Raval JS","Fukuta Y","Fernandez RE","Shoham S","Forthal DN","Abraham AG","Zhu X","Gerber JM"],"additional_accession":[]},"is_claimable":false,"name":"Early Treatment, Inflammation and Post-COVID Conditions.","description":"Background
Post-COVID conditions (PCC) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about early treatment, inflammation, and PCC.Methods
Among 883 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of CCP vs. control plasma with available biospecimens and symptom data, the association between early COVID treatment, cytokine levels and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14 and day 90 using a multiplexed sandwich immuosassay (Mesoscale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between COVID treatment, cytokine levels and PCC were examined using multi","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T18:51:04.422Z","creation":"2025-04-04T18:51:04.422Z"},"accession":"S-EPMC9949202","cross_references":{"pubmed":["36824860"],"doi":["10.1101/2023.02.13.23285855"]}}